The Sticking Point
Our client was launching a new biologic in the neurology space. However, it was the 13th drug to market and the 4th biologic entrant – i.e. ‘just another’ in the mix.
To use our narrative not just to drive uptake of our brand as an effective disease-modifying treatment (DMT), but to advocate for earlier DMT use thanks to the brand’s favourable risk–benefit profile.
A thought-provoking, sequentially planned campaign roll-out for the UK market with the intent on supporting anxious neurologists and their nurses on a journey to earlier DMT prescribing. 4 years on, this treatment is the market leader in the field.